IL6 and hepatocellular carcinoma: Remarkably, CAFs-derived IL-6 upregulates PD-L1 expression by activating the JAK-STAT3 signaling pathway of TANs, ultimately impairing T cell function and inducing immune tolerance in hepatocellular carcinoma(HCC) [69] (Fig. 1d).